Search the Newsreel

LeMaitre Vascular Down Over 22%, On Track for Largest Percent Decrease Since October 2008 -- Data Talk

LeMaitre Vascular Inc. (LMAT) experienced a significant drop of over 22%, trading at $82.06, which would mark its lowest close since January 2026. This decline puts the company on track for its largest percentage decrease since October 2008. The stock is down 30.1% from …

Earnings Preview: IMDX to Report Financial Results Post-market on August 10

This article announces that IMDX is scheduled to report its financial results after market close on August 10. The report will provide key insights into the company's performance, which investors and analysts will be watching closely.

LeMaitre Vascular (NASDAQ:LMAT) Price Target Cut to $94.00 by Analysts at Wells Fargo & Company

Wells Fargo & Company analysts have cut their price target for LeMaitre Vascular (NASDAQ:LMAT) to $94.00 from $104.00, maintaining an "equal weight" rating. This adjustment follows the company's recent earnings report where Q2 EPS of $0.74 missed the consensus estimate of $0.81, and revenue …

PB vs. CFR: Which Stock Should Value Investors Buy Now?

Investors interested in Banks - Southwest stocks are likely familiar with Prosperity Bancshares (PB) and Cullen/Frost Bankers (CFR). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We have …

Price to sales forward of Moleculin Biotech, Inc. – LS:A41SET

This article provides financial information for Moleculin Biotech, Inc. (A41SET) on the TradingView platform. It specifically highlights the "Price to sales forward" metric for the company, accessible through the Lang & Schwarz Tradecenter. The content itself is minimalist, primarily serving as a header for …

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces $0.25 Quarterly Dividend

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend of $0.25 per share, payable on September 3rd to shareholders of record on August 20th. This announcement comes despite the company missing analyst expectations for both Q2 revenue and EPS, and subsequently lowering its full-year 2026 …

LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Lowered by Barrington Research

Royal Bank of Canada Sells 18,448 Shares of LeMaitre Vascular, Inc. $LMAT

Royal Bank of Canada reduced its stake in LeMaitre Vascular, Inc. (LMAT) by 6.3% in the first quarter, selling 18,448 shares but still retaining a significant holding of 272,654 shares valued at $29.8 million. This comes as LeMaitre Vascular reported Q2 earnings that missed …

MOLECULAR PARTNERS AG (MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (MOLN)

Bernstein Liebhard LLP has issued a shareholder class action alert against Molecular Partners AG (MOLN), reminding investors of the upcoming September 12, 2022 deadline to file a lead plaintiff motion. The lawsuit, filed in the United States District Court for the Southern District of …

Agriculture & Natural Solutions Acquisition Corporation Revenue Breakdown – NASDAQ:ANSC

Clever Culture Doubles Big Pharma Customers as Its APAS Platform Gains Global Traction

Molecular Partners AG (MOLN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

China Partytime Schedules Board Meeting to Review Interim Results and Dividend

LeMaitre Vascular Inc (LMAT) (Q2 2026) Earnings Call Highlights: Strong EPS Growth and ...

iMDx to Release Second Quarter Results on August 10, 2026

Insight Molecular Diagnostics Inc. (iMDx) announced it will release its second-quarter 2026 financial results after market close on August 10, 2026, followed by a live Zoom webinar for discussion. Additionally, iMDx's CEO and CFO will participate in the 11th Annual Needham Virtual MedTech & …

Lazard Asset Management LLC Buys Shares of 124,353 Hercules Capital, Inc. $HTGC

Lazard Asset Management LLC has acquired 124,353 shares of Hercules Capital, Inc. (HTGC) worth approximately $1.84 million, representing 0.07% of the company's stock. Hercules Capital, a specialty finance company, exceeded its quarterly EPS estimates and increased its quarterly dividend to $0.40 per share, resulting …

Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History

This article details Ken Fisher's investment in 4D Molecular Therapeutics Inc (FDMT), held through Fisher Asset Management, LLC. As of June 30, 2026, he owns 65,751 shares valued at $874,490, representing 0% of his portfolio. Fisher has made one purchase of FDMT at an …

Form 144 4D Molecular Therapeutics For: 4 August By Investing.com

This article from Investing.com announces a Form 144 filing for 4D Molecular Therapeutics (FDMT) on August 4th. The content is brief, primarily serving as a placeholder for the filing information and is surrounded by typical financial news website navigation and market data. The article …

4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares

David Kirn, an insider at 4D Molecular Therapeutics (FDMT), sold 12,415 shares, bringing his total sales over the past year to 187,416 shares with no purchases. This selling activity, coupled with a lack of insider buying and a significant discount to the GuruFocus Value, …

LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates

LeMaitre Vascular (LMAT) reported Q2 earnings of $0.74 per share, falling short of the Zacks Consensus Estimate of $0.81, though it was an increase from $0.60 a year ago. The company's revenues of $70.38 million also missed expectations, despite being higher than the $64.23 …

LeMaitre Vascular (NASDAQ:LMAT) Issues Q3 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) has lowered its third-quarter 2026 earnings guidance, projecting EPS of $0.660–$0.710 and revenue of $66.3–$68.3 million, both below analyst consensus. The company also updated its full-year 2026 EPS guidance to $2.840–$2.940. Despite the lowered outlook, analyst sentiment remains "Moderate Buy" with …

FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades

An insider at 4D Molecular Therapeutics, Inc. (FDMT) plans to sell 26,842 Class A shares, valued at approximately $275,398.92, through Goldman Sachs & Co. LLC on or about August 4, 2026. These shares were originally acquired in a private transaction on December 15, 2020. …

How Investors Are Reacting To LeMaitre Vascular (LMAT) Slower Projected Revenue Growth And Mixed Earnings Track Record

Earnings call transcript: LeMaitre Vascular slips on Q2 2026 miss, cuts outlook

LeMaitre Vascular reported a Q2 2026 earnings and revenue miss, leading to a significant after-hours stock drop. Despite strong year-over-year growth and margin expansion, the company cut its full-year organic revenue growth outlook due to foreign exchange pressures, Middle East shipping delays, and cardiac …

4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan

David Kirn, President and CEO of 4D Molecular Therapeutics (FDMT), sold 12,415 shares of company stock on August 3, 2026, at a weighted average price of $10.0461 per share. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on January 9, 2026. …

Hercules Capital (HTGC) Could Be 13% Undervalued Following Earnings And Dividend News

Hercules Capital (HTGC) has garnered investor attention after reporting strong Q2 and H1 2026 results with higher revenue and net income. Despite a recent dip in its year-to-date share price, the stock is considered 13.2% undervalued by analysts, with a fair value target of …

LeMaitre says Artegraft is now approved in 56 countries

LeMaitre (NASDAQ: LMAT) reported strong Q2 2026 financial results with net sales up 10% year-over-year to $70.4 million and diluted EPS up 23% to $0.74. A key growth driver was Artegraft, whose sales increased by 34%, now representing 21% of total sales and approved …

Precision Trading with Oculis Holding Ag (OCS) Risk Zones

Oculis Holding Ag (OCS) shows divergent sentiment across different time horizons, suggesting choppy conditions with elevated downside risk. The article provides institutional trading strategies including long, momentum breakout, and short strategies, along with a multi-timeframe signal analysis detailing support and resistance levels. It emphasizes …

Moleculin Biotech (NasdaqCM:MBRX) Stock Forecast & Analyst Predictions

Moleculin Biotech (MBRX) is forecast to increase earnings by 54.7% and revenue by 74.8% annually, with EPS expected to grow by 75.4%. The company's lead drug candidate, Annamycin, is progressing through pivotal Phase 2/3 MIRACLE trials for relapsed or refractory acute myeloid leukemia (R/R …

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Exploring a 14.61% Potential Upside in the Healthcare Sector

LeMaitre Vascular, Inc. (LMAT) is a significant player in the healthcare sector, specifically in medical instruments for vascular surgery, with a market capitalization of $2.37 billion. The company shows strong financial health with 11.20% revenue growth, a 16.55% return on equity, and a forward …

LeMaitre Vascular earnings on deck as margin gains test continues

LeMaitre Vascular is set to announce its second-quarter earnings, with investors closely watching its ability to maintain significant margin expansion and accelerate profit growth. Analysts anticipate earnings of $0.81 per share on revenue of $71.5 million, reflecting substantial year-over-year growth. The company's premium valuation …

LeMaitre Q2 2026 Financial Results

LeMaitre Vascular, Inc. reported strong Q2 2026 financial results with sales up 10% to $70.4 million and EPS up 23% to $0.74, driven by a 34% increase in Artegraft sales and operational efficiencies. The company announced a quarterly dividend of $0.25/share and provided optimistic …

LeMaitre: Q2 Earnings Snapshot

LeMaitre Vascular Inc. (LMAT) reported a second-quarter profit of $17.1 million, or 74 cents per share, on revenue of $70.4 million. The medical device maker anticipates revenue for the current quarter to be between $66.3 million and $68.3 million, with full-year earnings projected at …

Sei Investments Co. Has $6 Million Position in Federal Agricultural Mortgage Corporation $AGM

Sei Investments Co. has increased its stake in Federal Agricultural Mortgage Corporation (AGM) by 48.1% in the first quarter, now holding 40,469 shares valued at approximately $6 million. Institutional investors collectively own 68.03% of the company, which recently exceeded quarterly earnings expectations and pays …

Insight Molecular Diagnostics updates financial calendar ahead of quarterly results webinar

Insight Molecular Diagnostics announced updates to its financial calendar, scheduling its Q2 2026 results webinar for August 10, 2026, at 5 p.m. ET. Additionally, management will participate in the Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026. This news brief was …

AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Second Quarter Fiscal 2026 Results

AirSculpt Technologies (NASDAQ: AIRS) announced it will release its second quarter 2026 financial results before market open on Monday, August 10, 2026, followed by a conference call at 8:30 a.m. Eastern Time. The company will also participate in Canaccord Genuity's 46th Annual Growth Conference …